Table 1.

Alterations in miR expression as a function of EWS/Fli1 or/and presumed cell of origin in Ewing sarcoma.

	Ban et al. (2011)	McKinsey et al. (2011)	Franzetti et al. (2012)	De Vito et al. (2011a)
miRs up in EwS	500	17/20a/106a/93	34c	19a/19b
	126*	484	573	17/20a/106a/106b/93
	93*	92a/92b/25	150	103/107
	505	15b	486	15b
	128	103/107	363	18a
	126	324-5p	556
	9	423-3p	9*
	101	320	632
	425*	let-7d	675
	592	106b*	520a*
	340*	130b	106a
	505*	760	302b*
	652	378	9
	150	532-3p	346
	20a*	665	1229
		886-5p	504
		574-5p	663
		940	1270
		296-3p	204
		186	490
		181d	20b
			622
			105
miRs down in EwS	145	146a/146b-5p	452	let-7 Family
	424	21	145	199a-5p/199a-3p
	21	22	144	27a/27b
	214*	100/99a/99b	143	24
	214	125b	205	193a
	28-5p	221/222	509	886-3p
	424*	584	190	145
	27a*	199a-5p/199a-3p	223	23a/23b
	22*	29a	31	22
	409-3p	27a/27b	767-3p	143
	21*	193b	30a-3p	100
	125b	549	511	221/222
	708	95	365	31
	135b	127-3p	517c	125b
		941	224	21
		203	450
		574-3p	574
		186*	668
		493	222
		922	34a
		30a	199b
		603	542-3p
			137
			30a-5p
			146a
			328

Data from expression profiling studies using EWS/Fli1 depletion (McKinsey et al., 2011; Franzetti et al., 2012), Ewing Sarcoma versus mesenchymal stem cell comparison (De Vito et al., 2011a), or both (Ban et al., 2011). MiRs with shared seed sequence are grouped. MiRs in bold were detected as differentially expressed in at least two of the studies. MiRs in italics were shown to affect cancer phenotype(s) in Ewing Sarcoma. “*” Denotes the generally less abundantly expressed miR strand. See text and references for further details.